In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654

被引:52
作者
Barret, Olivier [1 ]
Thomae, David [1 ]
Tavares, Adriana [1 ]
Alagille, David [1 ]
Papin, Caroline [1 ]
Waterhouse, Rikki [2 ]
McCarthy, Timothy [2 ]
Jennings, Danna [1 ]
Marek, Ken [1 ]
Russell, David [1 ]
Seibyl, John [1 ]
Tamagnan, Gilles [1 ]
机构
[1] Mol NeuroImaging MNI LLC, New Haven, CT 06510 USA
[2] Pfizer Global R&D, Groton, CT USA
关键词
PDE10A; PET imaging; kinetic modeling; test-retest; dosimetry; EMISSION-TOMOGRAPHY RADIOLIGAND; REFERENCE TISSUE MODEL; PHOSPHODIESTERASE INHIBITORS; QUANTIFICATION; STRIATUM; LIGAND; IDENTIFICATION; TRANSPORTER; RECEPTOR; TRACER;
D O I
10.2967/jnumed.113.122895
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate and is highly expressed in medium-sized spiny neurons of the striatum, making it an attractive target for novel therapies for a variety of neurologic and psychiatric disorders that involve striatal function. Potential ligands for PET imaging of PDE10A have been reported. Here, we report the first-in-human characterization of 2 new PDE10A radioligands, 2-(2-(3-(1-(2-fluoroethyl)-1H-indazol-6-yl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione (F-18-MNI-654) and 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione (F-18-MNI-659), with the goal of selecting the best one for use in future studies interrogating pathophysiologic changes in neuropsychiatric disorders and aiding pharmaceutical development targeting PDE10A. Methods: Eleven healthy volunteers participated in this study (F-18-MNI-654 test-retest, 2 men; F-18-MNI-659 test-retest, 4 men and 1 woman; F-18-MNI-659 dosimetry, 2 men and 2 women). Brain PET images were acquired over 5.5 h for F-18-MNI-654 and over 3.5 h for F-18-MNI-659, and pharmacokinetic modeling with plasma- and reference-region (cerebellar cortex)-based methods was performed. Whole-body PET images were acquired over 6 h for F-18-MNI-659 and radiation dosimetry estimated with OLINDA. Results: Both radiotracers were similarly metabolized, with about 20% of intact parent remaining at 120 min after injection. PET time activity data demonstrated that F-18-MNI-654 kinetics were much slower than F-18-MNI-659 kinetics. For F-18-MNI-659, there was good agreement between the Logan and simplified reference tissue models for nondisplaceable binding potential (BPND), supporting noninvasive quantification, with test-retest variability less than 10% and intraclass correlation greater than 0.9. The F-18-MNI-659 effective dose was estimated at 0.024 mSv/MBq. Conclusion: PET imaging in the human brain with 2 novel PDE10A F-18 tracers is being reported. Noninvasive quantification of F-18-MNI-659 with the simplified reference tissue model using the cerebellum as a reference is possible. In addition, F-18-MNI-659 kinetics are fast enough for a good estimate of BPND with 90 min of data, with values around 3.0 in the basal ganglia. Finally, F-18-MNI-659 dosimetry is favorable and consistent with values reported for other PET radiotracers currently used in humans.
引用
收藏
页码:1297 / 1304
页数:8
相关论文
共 40 条
[1]   NEW LOOK AT STATISTICAL-MODEL IDENTIFICATION [J].
AKAIKE, H .
IEEE TRANSACTIONS ON AUTOMATIC CONTROL, 1974, AC19 (06) :716-723
[2]  
[Anonymous], 1991, 1990 recommendations of the international commission on radiological protection ICRP publication 60, DOI 10.1016/0146-6453(91)90064-N
[3]   Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457:: re-evaluation of the validity of using a cerebellar reference region [J].
Asselin, Marie-Claude ;
Montgomery, Andrew J. ;
Grasby, Paul M. ;
Hume, Susan P. .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2007, 27 (02) :378-392
[4]   Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13) [J].
Bahn, Andrew ;
Hagos, Yohannes ;
Reuter, Stefan ;
Balen, Daniela ;
Brzica, Hrvoje ;
Krick, Wolfgang ;
Burckhardt, Birgitta C. ;
Sabolic, Ivan ;
Burckhardt, Gerhard .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (24) :16332-16341
[5]  
Barret O, 2012, J NUCL MED S1, V53
[6]  
CARSON R E, 1986, P347
[7]   Preclinical Evaluation of 18F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain [J].
Celen, Sofie ;
Koole, Michel ;
De Angelis, Meri ;
Sannen, Ivan ;
Chitneni, Satish K. ;
Alcazar, Jesus ;
Dedeurwaerdere, Stefanie ;
Moechars, Dieder ;
Schmidt, Mark ;
Verbruggen, Alfons ;
Langlois, Xavier ;
Van Laere, Koen ;
Andres, Jose Ignacio ;
Bormans, Guy .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (10) :1584-1591
[8]   Biochemistry and physiology of cyclic nucleotide Phosphocliesterases: Essential components in cyclic nucleotide signaling [J].
Conti, Marco ;
Beavo, Joseph .
ANNUAL REVIEW OF BIOCHEMISTRY, 2007, 76 :481-511
[9]   SPECTRAL-ANALYSIS OF DYNAMIC PET STUDIES [J].
CUNNINGHAM, VJ ;
JONES, T .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1993, 13 (01) :15-23
[10]   Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions [J].
Francis, Sharron H. ;
Blount, Mitsi A. ;
Corbin, Jackie D. .
PHYSIOLOGICAL REVIEWS, 2011, 91 (02) :651-690